Stereochemistry and drug efficacy and development: Relevance of chirality to antidepressant and antipsychotic drugs

Annals of Medicine

Volumn 34, Issue 7-8, 2002, Pages 537-543

  Baker, Glen B ^a   Prior, Trevor I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antidepressants; Antipsychotics; Chirality; Enantiomers; Stereochemistry

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BIOGENIC AMINE; CITALOPRAM; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; ESCITALOPRAM; FLUOXETINE; IBUPROFEN; LEVOMEPROMAZINE; MESORIDAZINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORCITALOPRAM; NORFLUOXETINE; PHENOTHIAZINE; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE;

CHIRALITY; DEPRESSION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG MIXTURE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENANTIOMER; HUMAN; ISOMER; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RACEMIC MIXTURE; REVIEW; STEREOCHEMISTRY;

EID: 0036948923     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/078538902321117742     Document Type: Review

References (65)

1. Lane RM, Baker GB. Chirality and drugs used in psychiatry: Nice to know or need to know? Cell Mol Neurobiol 1999; 19: 355-72.
2. Cahn RS, Ingold CK, Prelog V. The specification of asymmetric configuration in organic chemistry. Experientia 1966; 12: 81-124.
3. Caldwell J, Wainer IW. Stereochemistry: definitions and a note on nomenclature. Human Psychopharmacol Clin Exp 2001; 16: S105-7.
4. Coutts RT, Baker GB. Implications of Chirality and geometric isomerism in some psychoactive drugs and their metabolites. Chirality 1989; 1: 99-120.
5. Evans AM, Nation RH, Sansom LN, Bochner F, Somogyi AA. Stereoselective drug disposition: Potential for misinterpretation of drug disposition data. Br J Clin Pharmacol 1988; 26: 771-80.
6. Lee EJD, Williams KM. Chirality: Clinical pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 1990; 18: 339-45.
7. Tucker GT,Lennard MA. Enantiomer specific pharmacokinetics. Pharmacol Ther 1990; 45: 309-29.
8. Campbell DB. Selectivity in clinical pharmacokinetcs and drug development. Eur J Drug Metab Pharmacokinet 1990; 15: 109-25.
9. Evans AM. Enantioselective pharmacodynamics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992; 42: 27-56.
10. Gibaldi M. Stereoselective and isozyme-selective drug interactions. Chirality 1993; 5: 407-13.
11. Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001; 4: 185-200.
12. Caldwell J. Do single enantiomers have something special to offer? Human Psychopharmacol Clin Exp 2001; 16: S67-71.
13. Wainer IW. The therapeutic promise of single enantiomers: introduction. Human Psychopharmacol Clin Exp 2001; 16: S73-7.
14. Baumann P, Eap CB. Enantiomeric antidepressant drugs should be considered on individual merit. Human Psychopharmacol Clin Exp 2001; 16: S85-92.
15. Leonard BE. An introduction to enantiomers in psychopharmacology. Human Psychopharmacol Clin Exp 2001; 16: S79-84.
16. Hindmarch I. The enantiomer debate: current status and future directions. Human Psychopharmacol Clin Exp 2001; 16: S101-4.
17. Baldwin DS. Unmet needs in the pharmacological management of depression. Human Psychopharmacol Clin Exp 2001; 16: S93-9.
18. Hyneck M, Dent J, Hook J. Chirality: Pharmacological action and drug development. In: Brown C., ed. Chirality in Drug Design and Synthesis. London: U.K. Academic Press; 1990: 1-28.
19. Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 1989; 78: 695-715.
20. Caldwell J. Importance of Stereospecific bioanalytical monitoring in drug development. J Chromatogr A 1996; 719: 3-13.
21. Tucker GJ. Chiral switches. Lancet 2000; 355: 1085-7.
22. Gross G, Xin S, Gastpar M. Trimipramine: Pharmacological reevaluation and comparison with clozapine. Neuropharmacology 1991; 30: 1159-66.
23. Baumann P. Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI). Int Clin Psychopharmacol 1992; 6: 13-20.
24. Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 1995; 57: 411-41.
25. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropsychopharmacology 1992; 31: 997-1000.
26. Potts BD, Parli CJ. Analysis of the enantiomers of fluoxetine and norfluoxetine in plasma and tissue using chiral derivatization and normal-phase liquid chromatography. J Liq Chromatogr 1992; 15: 665-81.
27. Torok-Both GA, Baker GB, Courts RT, McKenna KF, Aspeslet LJ. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron capture detection. J Chromatogr 1992; 579: 99-106.
28. Eap CB, Gaillard N, Powell, K, Bauman P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. J Chromatogr 1996; 682: 265-72.
29. Pichini S, Pacifici R,Altieri I, Pellegrini M,Zuccaro P. Stereoselective determination of fluoxetine and norfluoxetine enantiomers in plasma samples by high pressure liquid chromatography. J Liq Chromatogr Rel Technol 1996; 19: 1927-35.
30. Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay, K, Kosel M, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001; 21: 330-4.
31. Stevens, JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993; 266: 964-71.
32. Agranat I, Caner H. Intellectual property and chirality of drugs. Drug Discov Today 1999; 4: 313-21.
33. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram resides in the S-(+) enantiomer. J Neural Trans 1992; 88: 157-60.
34. Kelsey JE, Nemeroff CB. Citalopram. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, seventh ed. Philadelphia: Lippincott Williams & Wilkins; 1999: 2435-8.
35. Rochat B, Amery M, Bauman P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monitor 1995; 17: 273-9.
36. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-6.
37. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102.
38. Horn AS, Snyder SH. Steric requirements for catecholamine uptake by rat brain synaptosomes: Studies with rigid analogs of amphetamine. J Pharmacol Exp Ther 1972; 180: 523-30.
39. Fuentes JA, Oleshansky MA, Neff NH. Comparison of the apparent antidepressant activity of (+)- and (-)-tranylcypramine in an animal model. Biochem Pharmacol 1976; 25: 801-4.
40. Hampson DR, Baker GB, Coutts RT. A comparison of the neurochemical properties of the stereoisomers of tranylcypromine in the central nervous system. Cell Mol Biol 1986; 32: 593-9.
41. Nicholson VJ, Pinder RM. In: Smith DF (ed.) Handbook of Stereoisomers: Drugs in Psychopharmacology. Boca Raton: CRC Press, 1984: 215-40.
42. Repchinsky C, ed. Compendium of Pharmaceuticals and Specialties (CPS). Ottawa: Canadian Pharmacists Association; 2002: 1855-8.
43. Schoemaker H, Berendsen HH, Stevens HJ, Nickolson VJ. Differences in presynaptic alpha-blockade, noradrenaline uptake inhibition, and potential antidepressant activity between (+)- and (-)-mianserin. Psychopharmacology (Berl) 1981; 74: 137-42.
44. Raiteri M, Maura G, Versace P. Functional evidence for two stereochemically different alpha-2 adrenoceptors regulating central norephinephrine and serotonin release. J Pharmacol Exp Ther 1983; 224: 679-84.
45. 3 receptors. J Pharm Pharmacol 1993; 45: 711-4.
46. 3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 1994; 33: 501-7.
47. Heinig R, Blaschke G. In vivo and in vitro Stereoselective metabolism of mianserin in mice. Arzneimittelforschung 1993; 43: 5-10.
48. Dahl ML, Tybring G, Elwin CE, Andreasson K, Gyllenpalm M, Bertilsson L. Stereoselective disposition of mianserin is related to debrisoquine hydoxylation. Clin Pharmacol Ther 1994; 56: 176-83.
49. Tybring G, Otani, K, Kaneko S, Mihara K, Fukushima, Bertilsson L. Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients. Ther Drug Monit 1995; 17: 516-21.
50. Eap CB, Powell K, Campussouche D, Monney C, Baettig D, Taeschner W, et al. Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mainserin-treated patients. Chirality 1994; 6: 555-63.
51. Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mainserin enantiomers. J Pharmacol Exp Ther 1996; 278: 21-30.
52. Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. Int Clin Psychopharmacol 1995; 2: 5-13.
53. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149-56.
54. Claghorn JL. Mirtazapine. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, seventh ed. Philadelphia: Lippincott Williams & Wilkins; 1999: 2390-7.
55. Dodd S, Burrows GD, Norman TR. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr 2000; 748: 439-43.
56. 2 receptors in rat brain. Neuropharmacology 1988; 27: 1117-24.
57. Kaiser C, Setler PE. Antipsychotic agents. In: Wolff, ME (ed.), Burger's Medicinal Chemistry, Part III, 4th ed., New York: John Wiley and Sons, 1981: 859.
58. Jortani SA, Poklis A. Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high-performance liquid chromatography. J Anal Toxicol 1993; 17: 374-7.
59. von Bahr C, Movin G, Nordin C, Liden A. Hammarlund-Udenaes M, Hedberg A, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234-9.
60. Brosen K. Recent developments in hepatic drug oxidation (implications for clinical pharmacokinetics). Clin Pharmacokinet 1990; 18: 220-39.
61. Eap CB, Guentert TW, Schaublin Loidl M, Stabl M, Koeb L, Powell K, et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59: 322-33.
62. Boireau A, Blanchard J-C, Garret C, Julou L. The use of thioproperazine, a phenothiazine derivative, as a ligand for neuroleptic receptors. II. In vivo studies. Biochem Pharmacol 1980; 29: 2339.
63. Müller MJ, Hartter S, Kohler D, Hiemke Ch. Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: A pilot study. Pharmacopsychiatry 2001; 34: 27-32.
64. Yashui-Furukori, N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29: 1263-8.
65. Shin J-G, Kane K, Flockhart DA. Potent inhibition of CYP2D6 by reduced haloperidol metabolites: Stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 2001; 5: 45-52.